Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

Abstract Background Epigenetic modulators may sensitize platinum-resistant ovarian cancer (PROC) to immune checkpoint inhibition by reprogramming the tumor microenvironment. Methods We report clinical and translational findings from a phase II non-randomized study of pembrolizumab and oral azacitidi...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Blair V. Landon, Julia L. Boland, Andrea E. Wahner Hendrickson, Deborah K. Armstrong, Boris Winterhoff, Jaime Wehr, Akshaya V. Annapragada, Christopher Cherry, Archana Balan, Guneet Kaleka, Victor E. Velculescu, Stephen B. Baylin, Cynthia A. Zahnow, Dennis J. Slamon, Gottfried E. Konecny, Valsamo Anagnostou, John A. Glaspy
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2026-02-01
Serie:	Communications Medicine
Accesso online:	https://doi.org/10.1038/s43856-026-01404-0
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!